Dr Boreham’s Crucible: Revenge of the nerd – Percheron’s new boss takes on cancer

Resumen detallado
Self-confessed science nerd Dr Michael Baker has restarted the engine of Percheron Therapeutics with the aim of getting the oncology ... Read More The post Dr Boreham’s Crucible:…
Percheron has revived itself as an oncology play. Pic: Tim Boreham/supplied
Dr Michael Baker, the new CEO of Percheron Therapeutics (ASX:PER), describes himself as “pretty boring, but in a good way”.
“I just love high-quality science with a disproportionate chance of success in a field I have a tremendous interest in.”
Boring? We would still strike up a chat with him at a party, albeit after a second drink.
This alleged dullness made Baker a walk-up start to head Percheron, which has revived itself as an oncology play after a catastrophic Duchenne muscular dystrophy trial (see below).
Baker was fresh from a six-year stint at Arovella Therapeutics, which he re-engineered from unsuccessful spray-delivery drug play Suda Pharmaceuticals to an early-stage cancer cell therapy developer.
Baker’s Percheron appointment is also notable because he eschewed a number of better-paid, bigger roles for the buzz of early-stage drug development.
“I don’t want to sound like a twerp, but I was quite lucky in that I got a number of opportunities to explore and some of them were quite sizeable,” he said.
“They had a lot of money, [but] I actually didn’t find it all that interesting.
Inicio del artículo, extracto de Stockhead. Para leer el resto, abra el artículo en el sitio del medio.
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (stockhead.com.au)




